Olashore Anthony A, Rukewe Ambrose
Department of Psychiatry, University of Botswana, Gaborone, Botswana.
Department of Anesthesia and Critical Care, University of Botswana, Gaborone, Botswana.
BMC Psychiatry. 2017 May 10;17(1):174. doi: 10.1186/s12888-017-1347-6.
There is a dearth of data on polypharmacy in child and adolescent mental health in Africa, especially Botswana where children and adults are treated in the same facility by general adult psychiatrists. This study was therefore designed to assess the prevalence and the risk factors of psychiatric polypharmacy among children and adolescents treated at Sbrana Psychiatric Hospital, Lobatse, Botswana.
Data involving socio-demographics, diagnosis (using ICD-10 classification) and pharmacological treatment were retrieved from the records of 120 children and adolescents aged below 18 years, between 1 January 2012 and 31 July 2016, who presented with psychiatric disorders. They were analysed with univariate and multivariate models.
The prevalence of psychiatric polypharmacy was 29.2%. Psychiatric co-morbidity (OR = 3.374, 95% CI: 1.177-9.9673) and psychotropic side effects (OR = 5.782, 95% CI: 1.636-20.430) were significantly associated with polypharmacy after regression analysis.
Psychiatric co-morbidity and psychotropic side effects were significant risk factors for polypharmacy in Botswana.
非洲儿童和青少年心理健康领域关于多药联用的数据匮乏，尤其是在博茨瓦纳，儿童和成人在同一机构由普通成人精神科医生进行治疗。因此，本研究旨在评估在博茨瓦纳洛巴策Sbrana精神病医院接受治疗的儿童和青少年中精神科多药联用的患病率及危险因素。
从2012年1月1日至2016年7月31日期间120名18岁以下患有精神疾病的儿童和青少年的记录中检索社会人口统计学、诊断（使用国际疾病分类第10版）和药物治疗数据。对这些数据进行单变量和多变量模型分析。
精神科多药联用的患病率为29.2%。回归分析后发现，精神科共病（比值比=3.374，95%置信区间：1.177 - 9.9673）和精神药物副作用（比值比=5.782，95%置信区间：1.636 - 20.430）与多药联用显著相关。
在博茨瓦纳，精神科共病和精神药物副作用是多药联用的重要危险因素。
